Qian Wang1, Junfen Ma1, Zhiyun Jiang1, Fan Wu1, Jiedan Ping1, Liang Ming2. 1. Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China. 2. Department of Clinical Laboratory, the First Affiliated Hospital of Zhengzhou University, Key Laboratory of Laboratory Medicine of Henan Province, Zhengzhou, Henan, China - mingliangzzu1203@163.com.
Abstract
BACKGROUND: Circulating microRNAs (miRNAs) have been increasingly suggested as biomarkers for numerous diseases. The aims of this study were to evaluate the expression of plasma miR-27a/b in patients with acute pulmonary embolism (APE) and determine the possibility of miR-27a/b as diagnostic biomarkers for APE. METHODS: Seventy-eight APE patients diagnosed by computed tomographic pulmonary angiography (CTPA) and 70 age and gender matched normal volunteers were included in this study. The levels of miR-27a and miR-27b were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and the concentrations of plasma D-dimer were measured using immunoturbidimetric assay. RESULTS: The levels of plasma miR-27a and miR-27b were significantly higher in APE patients (P<0.001) compared with normal controls. Receiver operating characteristic (ROC) curve analyses showed that plasma miR-27a was superior to miR-27b for the diagnosis of APE (AUC=0.784, AUC=0.707, respectively). Combining miR-27a or miR-27b with D-dimer significantly increased the diagnostic capacity of APE. CONCLUSIONS: Our results showed that circulating miR-27a and miR-27b might be potential novel diagnostic biomarkers in APE patients.
BACKGROUND: Circulating microRNAs (miRNAs) have been increasingly suggested as biomarkers for numerous diseases. The aims of this study were to evaluate the expression of plasma miR-27a/b in patients with acute pulmonary embolism (APE) and determine the possibility of miR-27a/b as diagnostic biomarkers for APE. METHODS: Seventy-eight APE patients diagnosed by computed tomographic pulmonary angiography (CTPA) and 70 age and gender matched normal volunteers were included in this study. The levels of miR-27a and miR-27b were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and the concentrations of plasma D-dimer were measured using immunoturbidimetric assay. RESULTS: The levels of plasma miR-27a and miR-27b were significantly higher in APE patients (P<0.001) compared with normal controls. Receiver operating characteristic (ROC) curve analyses showed that plasma miR-27a was superior to miR-27b for the diagnosis of APE (AUC=0.784, AUC=0.707, respectively). Combining miR-27a or miR-27b with D-dimer significantly increased the diagnostic capacity of APE. CONCLUSIONS: Our results showed that circulating miR-27a and miR-27b might be potential novel diagnostic biomarkers in APE patients.